Molecular technology company ArcherDX Inc disclosed on Tuesday the receipt of US Food and Drug Administration (FDA) breakthrough device designation to help accelerate the patient access for its companion diagnostic assay test for both liquid biopsy and tissue specimens.
The company added that the ArcherDx companion diagnostic assay is a sequencing-based test analyzing more than 50 genes intended for detection of somatic alterations in circulating tumor DNA (ctDNA) present in plasma and in RNA or DNA derived from formalin fixed paraffin embedded (FFPE) cancer tissue.
According to the company, the results of the ArcherDX companion diagnostic assay will be used to identify patients diagnosed with advanced non-small cell lung cancer for whom treatment with a specific targeted therapy is being considered.
Following approval, this test could be the first US FDA-approved multi-gene sequencing-based in-vitro diagnostic (IVD) to accept both plasma and FFPE-based inputs, concluded the company.
By combining patented Anchored Multiplexed PCR (AMP) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer platform dramatically enhances genetic mutation identification and discovery.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review